Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresec…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05677490
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Anchorage Associates in Radiation Medicine — Anchorage, Alaska
- Anchorage Radiation Therapy Center — Anchorage, Alaska
+ 781 more sites in the U.S.
Phase 2, Phase 3 Recruiting NIH
This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating patients with gastric or esophageal adenocarcinoma that may have spread from wh…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06203600
Locations: - Baptist Health Medical Center - Little Rock — Little Rock, Arkansas
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
- Kaiser Permanente-Anaheim — Anaheim, California
+ 368 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor recept…
Sponsor: AstraZeneca
NCT ID: NCT07431281
Locations: - Research Site — Phoenix, Arizona
- Research Site — Springdale, Arkansas
- Research Site — Duarte, California
+ 66 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to people with gastroesophageal cancer that is locally advanced (spread to nearby tissues) or has spread to o…
Sponsor: Pfizer
NCT ID: NCT07392892
Locations: - Rocky Mountain Cancer Centers, LLP — Aurora, Colorado
- Rocky Mountain Cancer Centers, LLP — Boulder, Colorado
- Rocky Mountain Cancer Centers, LLP — Centennial, Colorado
+ 54 more sites in the U.S.
Phase 3 Recruiting Industry
This is a Phase Ⅲ, randomized, open-label, Sponsor-blinded, 3-arm, global, multicenter study assessing the efficacy and safety of rilvegostomig in combination with fluoropyrimidine and T-DXd (Arm A) compared to trastuzumab, chemotherapy, a…
Sponsor: AstraZeneca
NCT ID: NCT06764875
Locations: - Research Site — Anchorage, Alaska
- Research Site — Phoenix, Arizona
- Research Site — Duarte, California
+ 47 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to measure the efficacy and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2.
Sponsor: AstraZeneca
NCT ID: NCT06346392
Locations: - Research Site — Birmingham, Alabama
- Research Site — Mobile, Alabama
- Research Site — Tucson, Arizona
+ 35 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of Pumitamig in combination with chemotherapy versus Nivolumab in combination with chemotherapy in participants with previously untreated advanced or metastatic gastric, gast…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07221149
Locations: - Local Institution - 0284 — Phoenix, Arizona
- Local Institution - 0437 — Los Angeles, California
- Local Institution - 0277 — Orange, California
+ 30 more sites in the U.S.
Phase 3 Recruiting Industry
This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with investigator-selected standard of care (SoC) therapy in Part 2…
Sponsor: RayzeBio, Inc.
NCT ID: NCT05477576
Locations: - Research Facility — Phoenix, Arizona
- Research Facility — Duarte, California
- Research Facility — Irvine, California
+ 29 more sites in the U.S.
Phase 3 Recruiting Industry
This is a double-blind, randomized, multiregion, comparative phase Ⅲ clinical study designed to evaluate the efficacy and safety of HLX22 in combination with trastuzumab and chemotherapy as first-line treatment in patients with HER2-positi…
Sponsor: Shanghai Henlius Biotech
NCT ID: NCT06532006
Locations: - Los Angeles Cancer Network — Anaheim, California
- OPN - Oncology Physician Network (Los Alamitos) — Los Alamitos, California
- Banner MD Anderson Cancer Center — Greeley, Colorado
+ 26 more sites in the U.S.
Phase 3 Recruiting Industry
Zolbetuximab is being studied in people with cancer in and around the stomach or where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer. Zolbetuximab with chemotherapy may be used to treat stomach …
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT06901531
Locations: - TOI Clinical Research — Cerritos, California
- The Angeles Clinic and Research Institute, West Los Angeles Office — Los Angeles, California
- Hartford HealthCare - Hartford Hospital — Hartford, Connecticut
+ 22 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of the current study is to evaluate the efficacy and safety of \[177Lu\]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive (SSTR+),…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06784752
Locations: - Mayo Clinic Arizona — Scottsdale, Arizona
- Highlands Oncology Group — Fayetteville, Arkansas
- Rocky Mountain Cancer Centers — Denver, Colorado
+ 16 more sites in the U.S.
Phase 3 Recruiting Industry
This clinical trial is designed to assess the efficacy and safety of the triplet combination of trastuzumab deruxtecan (ENHERTU, T-DXd, DS-8201a) plus a fluoropyrimidine plus pembrolizumab versus standard of care (SoC) chemotherapy plus tr…
Sponsor: Daiichi Sankyo
NCT ID: NCT06731478
Locations: - Yale Cancer Center — New Haven, Connecticut
- Orchard Healthcare Research Inc. — Skokie, Illinois
- University of Kansas Medical Center Research Institute, Inc. — Kansas City, Kansas
+ 15 more sites in the U.S.